FDA classifies medial knee implanted shock absorbers as Class II devices
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
The rule places medial knee implanted shock absorbers in FDA Class II, meaning they can be marketed under special safety and performance controls instead of facing the stricter Class III premarket approval route by default. Medical device manufacturers benefit from a clearer and less burdensome regulatory path, while hospitals, surgeons, and patients may see faster access to this type of orthopedic implant. Companies will still need to meet FDA special controls designed to show the device is safe and effective.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Classifies medial knee implanted shock absorbers as Class II medical devices
- Applies special controls to manage safety and effectiveness risks
- Reduces the regulatory burden compared with automatic Class III treatment
Obligations
What this law requires
Manufacturers marketing a medial knee implanted shock absorber in the United States must comply with FDA Class II special controls applicable to this device type to provide reasonable assurance of safety and effectiveness.